Hybrid simulation challenges and opportunities: a life-cycle approach

The last 10 years have witnessed a marked upsurge of attention on Hybrid Simulation (HS). The majority of authors define HS as a joint modelling approach which includes two or more simulation approaches (mainly Discrete Event Simulation, System Dynamics and Agent Based Simulation). Whilst some may argue that HS has been in existence for more than 5 decades, the recent rise tended to be more problem driven rather than technical experimentation. Winter Simulation Conference (WSC) 2015, 2016, 2017 have witnessed 3 panels on the purpose, history and definition of HS, respectively. This paper reports on a comprehensive review conducted by the panelists on HS and its applications. The aim of the paper is to move the debate forward by exploring potential platforms for developing concrete avenues for research on HS in conjunction with the modelling life cycle

Purpose and benefits of hybrid simulation: Contributing to the convergence of its definition

© 2018 IEEE. Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works

Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature

Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Over the past 25 years it has been suggested that health economic evaluation in the early stages may benefit the development and diffusion of medical products. Early health technology assessment has been suggested in the context of iterative economic evaluation alongside phase I and II clinical research to inform clinical trial design, market access, and pricing. In addition, performing early health technology assessment was also proposed at an even earlier stage for managing technology portfolios. This scoping review suggests a generally accepted definition of early health technology assessment to be “all methods used to inform industry and other stakeholders about the potential value of new medical products in development, including methods to quantify and manage uncertainty”. The present review also aimed to identify recent published empirical studies employing an early-stage assessment of a medical product. With most included studies carried out to support a market launch, the dominant methodology was early health economic modeling. Further methodological development is required, in particular, by combining systems engineering and health economics to manage uncertainty in medical product portfolios